These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

791 related items for PubMed ID: 19690023

  • 1. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Castellucci P, Fuccio C, Nanni C, Santi I, Rizzello A, Lodi F, Franceschelli A, Martorana G, Manferrari F, Fanti S.
    J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
    [Abstract] [Full Text] [Related]

  • 2. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
    Castellucci P, Ceci F, Graziani T, Schiavina R, Brunocilla E, Mazzarotto R, Pettinato C, Celli M, Lodi F, Fanti S.
    J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
    [Abstract] [Full Text] [Related]

  • 3. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
    Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, Allegri V, Montini GC, Ambrosini V, Boschi S, Martorana G, Marzola MC, Fanti S.
    Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
    [Abstract] [Full Text] [Related]

  • 4. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S, Coronado-Poggio M, García-Vicente AM, García-Garzón JR, Alonso-Farto JC, de la Jara AC, Maldonado-Suárez A, Rodríguez-Fernández A.
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [Abstract] [Full Text] [Related]

  • 5. Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution.
    Marzola MC, Chondrogiannis S, Ferretti A, Grassetto G, Rampin L, Massaro A, Castellucci P, Picchio M, Al-Nahhas A, Colletti PM, Marcolongo A, Rubello D.
    Clin Nucl Med; 2013 Jan; 38(1):e26-32. PubMed ID: 23242060
    [Abstract] [Full Text] [Related]

  • 6. [First results of PET / CT-guided secondary lymph node surgery on patients with a PSA relapse after radical prostatectomy].
    Winter A, Uphoff J, Henke RP, Wawroschek F.
    Aktuelle Urol; 2009 Sep; 40(5):294-9. PubMed ID: 19533582
    [Abstract] [Full Text] [Related]

  • 7. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G, Picchio M, Parra RG, Briganti A, Gianolli L, Montorsi F, Messa C.
    Clin Nucl Med; 2012 Apr; 37(4):325-31. PubMed ID: 22391699
    [Abstract] [Full Text] [Related]

  • 8. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP).
    Panebianco V, Sciarra A, Lisi D, Galati F, Buonocore V, Catalano C, Gentile V, Laghi A, Passariello R.
    Eur J Radiol; 2012 Apr; 81(4):700-8. PubMed ID: 21330082
    [Abstract] [Full Text] [Related]

  • 9. Relationship between PSA kinetics and Tc-99m HYNIC PSMA SPECT/CT detection rates of biochemical recurrence in patients with prostate cancer after radical prostatectomy.
    Liu C, Zhu Y, Su H, Xu X, Zhang Y, Ye D, Hu S.
    Prostate; 2018 Dec; 78(16):1215-1221. PubMed ID: 30027591
    [Abstract] [Full Text] [Related]

  • 10. (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy.
    Ceci F, Castellucci P, Mamede M, Schiavina R, Rubello D, Fuccio C, Ambrosini V, Boschi S, Martorana G, Fanti S.
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):149-55. PubMed ID: 23151910
    [Abstract] [Full Text] [Related]

  • 11. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P, Katcher J, Levin H, Zippe C, Klein E.
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [Abstract] [Full Text] [Related]

  • 12. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
    Delongchamps NB, Zerbib M, Mejean A, Rouach Y, Debre B, Peyromaure M.
    Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
    [Abstract] [Full Text] [Related]

  • 13. Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis.
    Treglia G, Ceriani L, Sadeghi R, Giovacchini G, Giovanella L.
    Clin Chem Lab Med; 2014 May; 52(5):725-33. PubMed ID: 24310773
    [Abstract] [Full Text] [Related]

  • 14. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis.
    Farsad M, Schiavina R, Castellucci P, Nanni C, Corti B, Martorana G, Canini R, Grigioni W, Boschi S, Marengo M, Pettinato C, Salizzoni E, Monetti N, Franchi R, Fanti S.
    J Nucl Med; 2005 Oct; 46(10):1642-9. PubMed ID: 16204714
    [Abstract] [Full Text] [Related]

  • 15. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy.
    Shen S, Lepor H, Yaffee R, Taneja SS.
    J Urol; 2005 Mar; 173(3):777-80. PubMed ID: 15711268
    [Abstract] [Full Text] [Related]

  • 16. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA, Halvorsen OJ, Daehlin L, Hostmark J, Akslen LA.
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [Abstract] [Full Text] [Related]

  • 17. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer.
    Seltzer MA, Barbaric Z, Belldegrun A, Naitoh J, Dorey F, Phelps ME, Gambhir SS, Hoh CK.
    J Urol; 1999 Oct; 162(4):1322-8. PubMed ID: 10492189
    [Abstract] [Full Text] [Related]

  • 18. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G, Picchio M, Scattoni V, Garcia Parra R, Briganti A, Gianolli L, Montorsi F, Messa C.
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1106-16. PubMed ID: 20306038
    [Abstract] [Full Text] [Related]

  • 19. Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database.
    Chang SL, Freedland SJ, Terris MK, Aronson WJ, Kane CJ, Amling CL, Presti JC.
    Urology; 2010 Feb; 75(2):439-44. PubMed ID: 19819536
    [Abstract] [Full Text] [Related]

  • 20. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H.
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.